INmune Bio

Yahoo Finance • 2 months ago

INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift

Earnings Call Insights: INmune Bio (INMB) Q2 2025 MANAGEMENT VIEW * David J. Moss announced his appointment as Chief Executive Officer following the retirement of co-founder RJ Tesi, stating, "I'm honored to address you today as the ne... Full story

Yahoo Finance • 2 months ago

INmune Bio August 2025 slides: three-platform strategy shows clinical progress

Introduction & Market Context INmune Bio Inc (NASDAQ:INMB) presented its corporate strategy and clinical progress in August 2025, highlighting advances across its three immunomodulatory platforms. The biotech company, which focuses on ha... Full story

Yahoo Finance • 2 months ago

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, to... Full story

Yahoo Finance • 2 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock... Full story

Yahoo Finance • 2 months ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company, today... Full story

Yahoo Finance • 2 months ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will b... Full story

Yahoo Finance • 3 months ago

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its... Full story

Yahoo Finance • 3 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on... Full story

Yahoo Finance • 3 months ago

INmune Bio stock downgraded by Raymond James after Alzheimer's trial miss

Investing.com - Raymond James downgraded INmune Bio Inc. (NASDAQ:INMB) from Outperform to Market Perform following disappointing Phase 2 trial results for the company’s XPro therapy in early Alzheimer’s disease. The stock has fallen over... Full story

Yahoo Finance • 3 months ago

INmune Bio fails to meet main goal in Alzheimer's treatment study

[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Shares of INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) dropped on Monday after the company did not achieve the main goal in a mid-stage trial for i... Full story

Yahoo Finance • 3 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings

[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 3 months ago

INmune Bio reverses early gains after stock offering

[Recession] AndrewJohnson * Following sharp gains in the morning hours, INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) fell ~11% during the afternoon session on Friday after the Alzheimer’s drug developer announced an e... Full story

Yahoo Finance • 3 months ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with tw... Full story

Yahoo Finance • 3 months ago

INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug

[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images * Shares of INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) extended after-hours gains in the pre-market trading on Friday with a ~61% rise as Wall... Full story

Yahoo Finance • 3 months ago

Why INmune Bio Is Rising In Pre-market?

(RTTNews) - INmune Bio Inc. (INMB) said it will host a conference call on June 30 to present top line data from the Phase 2 MINDFuL trial in early Alzheimer's Disease. Shares of INmune Bio are up 72% in pre-market trade on Friday. The MIN... Full story

Yahoo Finance • 3 months ago

INmune Bio to present Phase 2 Alzheimer's trial data on June 30

BOCA RATON - INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotech company with a market capitalization of $144.6 million and shares trading at $6.28, will host a conference call on Monday, June 30 at 8:00 AM EDT to present top line data... Full story

Yahoo Finance • 3 months ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology comp... Full story

Yahoo Finance • 4 months ago

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

XPro™ Treatment Post-TBI Prevents Short- and Long-Term Alzheimer’s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation... Full story

Yahoo Finance • 5 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s D... Full story